Navigation Links
New non-surgical treatment for common, vexing eye condition
Date:3/31/2014

Baltimore, MD, 31 March 2014. A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

The newly published report shows that eye drops containing the anti-anginal drug dipyridamole (Persantin, Cardoxin) led to almost total disappearance of an inflamed pterygium in a 35 year old otherwise healthy woman.

Dipyridamole is a drug in use over the past 55 years to treat other disorders, but now found to have this remarkable new use.

Pterygium is a disorder in which a non-cancerous growth develops on the white conjunctiva of the eye and over time invades the cornea. In some countries it affects up to 25% of the population. As the growth spreads, patients can develop vision problems as well as significant discomfort from complications such as dry eye, inflammation, irritation, and foreign body sensation. Additionally, because of their location in the eyes, pterygia are a cause of substantial cosmetic concern for sufferers.

Until now, eye surgery has been the only curative option, aided by medications trying to lessen the disorder's symptoms. However, even after eye surgery, pterygia often recur.

The new report's lead author, Moshe Rogosnitzky, who is Co-Founder and Director of Research at the MedInsight Research Institute, discovered that administration of dipyridamole eye drops significantly reduced a pterygium and completely resolved the associated inflammation and other symptoms.

Clinical trials are now being plannedfor pterygia, pingueculae, and other common eye disorders and their complications such as dry eye and inflammation.

One particular advantage to this discovery is that dipyridamole is a widely-approved anti-thrombosis medication that has been in use for over 55 years. Its safety profile is well-established; as such, fast-track development of dipyridamole eye drops as a repurposed drug is feasible.

Moshe Rogosnitzky commented on this finding, "Pterygium and dry eye are debilitating disorders for which new safe solutions are urgently needed, and I believe dipyridamole has the potential to provide relief to sufferers of these intractable conditions.

Rogosnitzky, who specializes in finding new uses for old drugs, continued, "This is yet another example of the advantages of drug repurposing. Whereas bringing a new drug to market can take up to 17 years or more, finding a new use for an old drug with an excellent safety profile can lead to approval and availability in as little as two years."


'/>"/>
Contact: Deena Illions
deena1@medinsight.org
443-927-7755
MedInsight Research Institute
Source:Eurekalert  

Related medicine news :

1. Masha Banar, Board Certified Physician Associate, Now Offers Non-Surgical Rhinoplasty for Correction of Complications After Surgical Rhinoplasty
2. Cosmetic Laser Institute in Orange County Introduces Non-Surgical Fat Reduction with Exilis
3. Barnes-Jewish Hospital Offering New FDA-approved Non-surgical Procedure for Mitral Valve Repair
4. Lipo Body Sculpture of Houston Announces Breakthrough Treatment for Non-Surgical Neck Tightening
5. Masha Banar, PA-C of Visage Sculpture, Non-surgical Face Shaping Cosmetic Practice of Boston, Confirms Resistance Forming to Botox over Time, Less to Dysport.
6. Non-surgical Facelift, Specialty of Masha Banar PA-C of Visage Sculpture, Got a "Lift": Retrospective Comparison of Radiesse, Sculptra, and Perlane
7. Horwitz Dermatology Now Offers Non-Surgical Ultrasound Skin Tightening Treatments
8. Brandith Irwin, MD, of SkinTour.com Answers New Blog Question About Improving Neck Skin Non-Surgically
9. Visage Sculpture, Non-Surgical Face Shaping Cosmetic Practice of Boston, Announces Using Microcannulas to Make Non-Surgical Rhinoplasty Safer
10. Living Well Medical Introduces Groundbreaking Non-Surgical Therapies for Osteoarthritis Knee Pain
11. Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New non-surgical treatment for common, vexing eye condition
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: